The oncogenic activity of TRIB2 is linked to its dysregulated expression, rather than to mutational activation, as in the case of melanoma and colorectal cancer, where TRIB2 is overexpressed and inversely correlated with survival of patients [49]. Here, TRIB2 is linked to melanoma.